Investigation of the chronic ulcerogenic effects of CT-3 and indomethacin in rats
| Parameter | ED50 | |
|---|---|---|
| CT-3 | Indomethacin | |
| mg/kg/day (S.E.M.)6-a | ||
| Ulcers | ||
| Corpus | >30.0 | 7.8 (1.4) |
| Antrum | >30.0 | 10.6 (3.4) |
| Duodenum | >30.0 | 10.1 (5.5) |
| Jejunum | >30.0 | 6.1 (2.5) |
| Ileum | >30.0 | 3.1 (1.1) |
| Colon | >30.0 | 10.1 (4.8) |
| Adhesions | ||
| Duodenum | >30.0 | 10.1 (6.7) |
| Jejunum | >30.0 | 4.2 (1.4) |
| Ileum | >30.0 | 19.0 (14.5) |
| LD50 (S.E.M.) | ||
| Day 5 | 7.8 (1.8) | |
Test drugs CT-3 and indomethacin were administered in a suspension containing 25% DMSO and 0.25% MC solution. Drugs were administered for 5 days.
↵6-a CT-3 at the highest tested dose of 30 mg/kg/day did not induce any ulcerations, adhesions, or deaths in the rats.